Connect with us

Industry News

Wayland Releases Portfolio of Brands & Receives Sales License from Health Canada for Expansion Site

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, Oct. 17, 2018 (GLOBE NEWSWIRE) — Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company“) is excited to announce the release of its portfolio of brands that cater to different ages, genders, and occasions. The Company’s extensive research created a portfolio of brands, each designed to address segments of the cannabis market both present and future.  Strategically using each of these brands, Wayland gave itself the ability to be present and relevant to consumers.
“The advent of recreational cannabis legalization in Canada is truly a watershed moment for Canadians. As we lead the world by example on another modern and controversial issue, we are thrilled to be at the forefront to welcome this new age. As a company invested in the long-term growth of the legal cannabis industry, first in providing state-of-the-art, highest-quality medicinals and now, a breadth of recreational products formulated with the same pharmaceutical standards, we know this is just the first step towards educating and demonstrating to the naysayers that legalization is the right path.“The responsibility now lies with us, the companies behind the products, to show through professionalism and dedication to the highest integrity and operating standards that the benefits far outweigh the risks and that slow and steady wins the race. Working closely with government and our peers to ensure education and safety remain top of mind has been the Company’s operating edict since its humble beginnings on a farm in Norfolk, ON. We have now received the sales license from Health Canada for our expansion in Norfolk and will be able to ship product grown in our state-of-the-art facility,” said Ben Ward, CEO Wayland Group.Rather than taking a one-size-fits-all approach, Wayland has taken a purposeful and consumer-centric approach to each of its brands and offerings, which was validated with local consumer research. Brands within the portfolio will represent the quality and consistency that Wayland Group is globally recognized for, in addition to satisfying consumer needs.KIWI
Fun and approachable.  Kiwi will be the brand people will look to make “all things cannabis” make sense. Designed for light users who are new to the category and looking to better understand cannabis.
HIGH TIDE
High Tide is Wayland’s collection of high-THC cannabis strains designed for experienced medium to heavy users.  
NORTHERN HARVEST
Northern Harvest has something for any cannabis consumer that appreciates authentic, local quality. Designed for light / medium users who enjoy Cannabis.
LOST AT SEED
Lost at seed is a meticulously curated collection of the finest and most rare cannabis genetics. Designed for medium to heavy users who are looking for highly desirable and impossible to find strains.
SOLARA C
Solara C will be designed exclusively to produce only the highest quality CBD products. Solara C will strive to educate and give consumers the ability to experience a natural, non- pharmaceutical alternative.
RARE DANKNESS
This partner brand will be for experienced cannabis users who are knowledgeable about strains, potencies and profiles.  It will offer a wide selection of premium award-winning strains that users won’t be able to find anywhere else.
Kiwi, Northern Harvest, and High Tide will be available in select markets on October 17th, 2018.Fast forward to today and our state-of-the-art, heavily automated, food-grade production facilities, investments in leading edge absorption technologies, products focused on the needs of every consumer, a deeply experienced team who have done this before in other legalized markets, and we believe Wayland is poised to deliver on our promise to improve lives through cannabis every day.Today, Canada takes a leadership position among its global peers, many of which we are working with as they follow down the cannabis legalization path. As a country, we will lead by example. And while there is a lot of noise in the industry as we enter into this era, as is often the case, the future is brightest for those who focus on the work at hand. Success will lie with those who quietly build companies dedicated to customer experiences focused on quality, value and a commitment to getting it right.Welcome to your future, Canada. We’re excited to be a part of it. Ben Ward, CEO, Wayland GroupMaricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details see the press release dated September 24, 2018.About Wayland GroupWayland is a vertically integrated producer and distributor of marijuana for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal license from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Wayland is currently undertaking an expansion of its cultivation and support facilities in Canada and will continue to pursue new opportunities in Europe.Forward Looking StatementsThis news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.For more information about Wayland, please visit our website at www.waylandgroup.comCONTACT INFORMATION
Investor Relations
Graham Farrell
VP, Communications
Graham.Farrell@waylandgroup.com
647-643-7665
Media Inquiries: media@waylandgroup.com

Corporate Headquarters (Canada)
Wayland Group (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

Original story can be found at: http://globenewswire.com/news-release/2018/10/17/1622646/0/en/Wayland-Releases-Portfolio-of-Brands-Receives-Sales-License-from-Health-Canada-for-Expansion-Site.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

NutraLife Biosciences, Inc. (NLBS) Reports First Quarter 2019 Results

Avatar

Published

on

default_cannabis_industry_cannamaps

Coconut Creek, FL, May 17, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraLife Biosciences Inc. (“NutraLife” or “NLBS”), (OTC Markets OTCQB: NLBS) today announced financial results for its fiscal 2019 first quarter ended March 31, 2019. The Company posted quarterly revenue of $720,799 and quarterly loss per diluted share of $0.01. These results compare to revenue of $722,905 and loss per diluted share of $0.01 for the same quarter of last year.  For the quarter ended March 31, 2019, the Company’s total assets were $4,462,098 compared to $1,830,329 for the same quarter in 2018, an increase of 144%.
For the Three Months Ended March 31, 2019Q1 2019, Sales for Q1 2019 were $720,799 compared to $722,905 for the same period in 2018.Q1 2019, Cash & Cash Equivalents at the End of the Period were $676,822 compared to $151,707 for the same period in 2018.Q1 2019, Proceeds from the sale of stock was $2,224,480 compared to $0 for the same period in 2018.Q1 2019, Receivables increased to  $115,484 at March 31, 2019 from $54,082 for the same period in 2018.Q1 2019, Loss from Operations was $994,306 compared to $595,561 for the same period in 2018. Q1 2019, Cash used by operations was $1,208,126 compared to $6,900 for the same period in 2018.Q1 2019, General & Administrative Expenses were $901,167 compared to $418,422 for the same period in 2018.The Loss from Operations is the result of increases in expenses related to the Company’s positioning for growth.  The Company incurred significant expenses related to the purchase of supplies and inventory needed to support an increase in production capacity. In addition, the Company needed to increase its staffing resulting in higher payroll costs during the quarter.  These increases directly impacted the costs of sales for this quarter. Other expenses were incurred related to research and development and marketing costs that directly impacted the Company’s general and administrative expenses for the quarter.The Company incurred costs from investing activities aggregating $859,507 that consist of the purchase of property and equipment totaling $729,507 and the acquisition of intellectual property of $130,000.  The property and equipment represent payments made towards the construction of a 9,000 square foot modular “clean room” and processing equipment for use at the Company’s new facility. The intellectual property is a patent for a dermal patch to prevent bites from insects, including mosquitoes.“We are pleased to report our 1st quarter 2019 financial results and an increase in the Company’s total assets of more than 144% to $4,462,098 compared to $1,830,329 for the same period in 2018,” said Edgar Ward, NutraLife’s Chief Executive Officer. “The results reflect the Company’s investment in and expansion of its operations, manufacturing capacity and vertical integration into the life sciences industry.”The statements herein are qualified in their entirety to the Company’s financial statements included in its Quarterly Report on Form 10-Q for the period ended March 31, 2019, filed with the Securities & Exchange Commission on May 15, 2019.About NutraLife BioSciencesEdgar Ward founded NutraLife in 2010 and since that time he has served as its Chief Executive Officer, President and Director. Under Mr Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration, and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products that support daily health and wellness uses.Forward-Looking StatementsThis press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) ). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to process hemp with GEG will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applies.Company Contact:NutraLife BioSciences, Inc.6601 Lyons Road, Suite L-6Coconut Creek, FL  33073Telephone 888-509-8901www.NutraLifeBioSciences.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/05/17/1827015/0/en/NutraLife-Biosciences-Inc-NLBS-Reports-First-Quarter-2019-Results.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Aura Announces Strategic Entry Into the European Market With the Closing of the Acquisition of Pharmadrug

Avatar

Published

on

default_cannabis_industry_cannamaps

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
TORONTO, May 17, 2019 (GLOBE NEWSWIRE) — Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the previously announced (May 8, 2019) acquisition of an 80% equity interest in Pharmadrug Production GmbH (“Pharmadrug”) for total consideration of €5.0 million. Pharmadrug is a cash flow positive German pharmaceutical distribution company with over 20 years of operating history and a Schedule I European Union narcotics license allowing for the distribution of medical cannabis to pharmacies in Germany and throughout the Eurozone as markets become legalized. Pharmadrug has supply agreements in place with Bedrocan International B.V., Canadian Licensed Producers, and is currently supplying medical cannabis to pharmacies in Germany.Daniel Cohen, CEO of Aura, commented, “This is a historic day in the early life of Aura, having closed on our first flagship transaction. This acquisition establishes Aura in the European market as a medical cannabis supplier in Germany and opens doors to opportunities throughout the rest of the continent. Pharmadrug is a strong strategic fit with our Israel cultivation project and the opening of the Israeli export law. We now have a strategic avenue to export our own medical cannabis from Israel into the European Union. In addition, we plan to significantly grow the Pharmadrug business through additional supply agreements with other Canadian, Israeli, and European LPs.”The Company has satisfied the escrow release conditions pursuant to its previously announced private placement of a cumulative amount of 21,545,454 subscription receipts (each, a “Subscription Receipt”) at a price of $0.22 per Subscription Receipt for gross proceeds of approximately $4.74 million and has successfully drawn $3 million from its previously announced bridge facility (see the press release issued by Aura on May 8, 2019).Resignation of Mr. FreudmanAura also announces that Joel Freudman has resigned as a director in order to focus on his other business ventures. Aura thanks Mr. Freudman for his corporate governance advice while also helping the Company through its first audit as a publicly-traded company. The Company is in discussions with other qualified candidates to replace Mr. Freudman and will be making an announcement once such replacement has been confirmed.About Aura Health Inc.Aura Health is building an international network of vertically integrated cannabis assets. Through an established product line of cannabis-infused edible products and oil extracts, Aura is dedicated to building a high margin downstream business in the medical marijuana sector. The Company owns 80% of Pharmadrug, a German medical cannabis and pharmaceutical distributor, as well as debt that converts to 54% equity of HolyCanna, a cultivation and nursery license holder in Israel. Aura also has a binding letter of intent to purchase CannabiSendak, the builder of a network of high-profile dispensaries in Israel.For further information, please contact:Daniel Cohen, CEO
Aura Health Inc.
(647) 202-1824
David Posner, Chairman
Aura Health Inc.
(647) 985-6727
Caution Regarding Forward-Looking Information:THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of Pharmadrug or Aura. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include reference to Aura’s expansion through Europe, and the entering into of additional supply agreements, among others. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals, owning interests in companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history, reliance on management, requirements for additional financing, competition, hindering market growth; regulatory and political change.All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Original story can be found at: http://www.globenewswire.com/news-release/2019/05/17/1826999/0/en/Aura-Announces-Strategic-Entry-Into-the-European-Market-With-the-Closing-of-the-Acquisition-of-Pharmadrug.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

HPIL HOLDING issues comprehensive shareholder update

Avatar

Published

on

default_cannabis_industry_cannamaps

MIDLAND, Mich., May 17, 2019 (GLOBE NEWSWIRE) — HPIL Holding (the “Company”) (OTC PINK: HPIL) is pleased to issue a comprehensive shareholder update addressing the status of the company and its subsidiaries.
The Company and the Company’s wholly owned subsidiaries MyFly WiFi Inc., RodDoc Inc., Crypto Currency Engine Inc., Karate Games Company Inc., Global Live Streaming Inc., HPIL Real Estate LLC. have been incorporated in Wyoming. HPIL Holding and nuUnlimited Ltd. UK jointly owned subsidiary nuUnlimited North America Inc. has also been incorporated in Wyoming. A relevant 8K was filed on  March 15, 2019.The Company has signed a Letter of Intent to purchase property located at 278 E Saginaw Rd, Sanford, MI 48657. A relevant 8K was filed on  April 17, 2019.MyFly WiFi Inc. is a Proximity Marketing Company. Proximity Marketing, also referred to as Location Aware Advertising (LAA), enables mobile users to receive an advertising message or other customizable content based on their location. LAA allows advertisers to deliver highly customized promotions, coupons and offers to a highly primed individual, specifically taking into account their geographical location, as well as the time of day and other variables. Also, LAA lets advertisers reach their customers when they are primed to make a purchase. MyFly WiFi is finalizing negotiations to market and license our technology in India and use an Indian supplier for some of our back office functions. We are also working with nuUnlimited Limited in the UK to license our technology to them for their UK market. “We recognized the potential for smart locations some time ago and are excited to be able to bring a complete solution together with MyFlyWifi over the coming months,” states Tim Sandford, CEO of nuUnlimited. The project integration work will be carried out in conjunction at nuUnlimited’s development hub in Scotland and at MyFlyWiFi’s offices in Boca Raton, Florida, USA  before the first product is launched in the final quarter of the year globally.nuUnlimited North America Inc. (NUNA) We are in the process of engaging and bringing on the HPIL team a seasoned manager from a major telecom company to be the President of NUNA. Our initial concentration is selling to Cannabis companies that need to track the provenance of the cannabis from plant to consumer. A white paper on Cannabis is available at http://hpilholding.com/download/Cannabispaper[1127].pdf.  Many Michigan Cannabis companies are locating in the Pinconning Michigan area which is very close to our offices and assisting us in our development and marketing efforts in the Cannabis field.RodDoc Inc. builds “spiral banding machines” that resurface worn underground drilling rods saving companies thousands in unnecessary expenses.  On February 21, 2019 the U.S. Patent and Trademark Office published U.S. Patent Application No. 2019-0056045-A10 (“Spiral Banding”). The claims of the newly issued patent application are generally directed towards methods of spiral rod banding and identification, including performance of actions following therefrom. The Application generally permits patentees to be eligible for a reasonable royalty for infringement occurring between the publication date and the date the patent is granted. A relevant 8K was filed on  March 12, 2019.RodDoc has been doing business and marketing to horizontal directional drilling (HDD) companies in Southern New Jersey.  RodDoc’s product and services have been well received and expansion plans are in place.  As proprietary machines are built and deployed, we expect the high value-added proposition to rapidly grow the business. The market for HDD has significantly increased in recent years.In addition to US domestic deployment, HPIL Holding has initiated discussions with parties in other countries to license and install the RodDoc patent pending process and “Spiral Banding Machine”.  The initial target markets include Canada and Europe. Mr. Christopher Philbrick, President of RodDoc, said, “We are working closely with industry experts to develop testing methods to minimize risk of failure while drilling. We are  seeking to make NDT (non destructive testing) reporting standard prior to initiating marketing and growing and expanding our geographic market. This will eliminate a significant hurdle in our business and give customers the peace of mind that they need.”Karate Games Company Inc. Mr. Ionel Bara, President and Founder of WTOKF (the World Traditional Okinawa Karate Federation), said: “We are consulting with the HPIL development team to define the parameters for the games. We have decided with HPIL to include many of our activities for authentic content. The 2020 Olympics will debut Karate for the first time“. Ray Wong, COO of HPIL commented:“We look forward to helping the WTOKF to expose the ancient sport of karate to a new audience using modern technology.”Global Live Streaming Inc. Mr. Ionel Bara President and Founder of WTOKF said: “We look forward to monetizing our vast library of Karate videos and future events. We will provide HPIL with everything that is needed to make these karate games work . We are confident that it will be a real success, and beneficial to our membership.”HPIL Real Estate LLC. As previously announced HPIL has signed a Letter of Intent to purchase property located at 278 E Saginaw Rd, Sanford, MI 48657. A relevant 8K was filed on  April 17, 2019.  Mr. Nitin Amersey, Chairman and CEO of HPIL, said, “This property will serve as HPIL Holdings corporate headquarters, main offices of our nuUnlimited North America Inc. Joint Venture and as the primary refurbishment center for our wholly owned RodDoc subsidiary.”Mr. Amersey, stated, “This action of incorporating our businesses in Wyoming provides us with considerable savings annually in state registration expenditures. The Company’s trading symbol on the OTC will remain unchanged as ‘HPIL.’” Mr. Amersey, also noted, “Our management team is working diligently and effectively to realize our goals. We have many positives at play and intend to keep our shareholders informed as we progress forward. We are actively looking to expand our management team for our various businesses at this time. Our newly appointed CFO Mr. David Langle is working diligently to get us current in our reporting to the SEC.”HPIL Holding (http://hpilholding.com) is a diversified holding company listed on OTC Markets. HPIL Holding is focused on investing in both private and public companies in differing business sectors. HPIL Holding does not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, acquires various types of businesses. HPIL Holding also evaluates the acquisition of intellectual properties and technologies.Safe Harbor / Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “plan,” “potential,” “seek,” and “intend,” among others. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ include, but are not limited to, substantial competition; our possible need for financing; uncertainties of technological changes; and dependence upon third parties. The Company does not undertake an obligation to update or revise any forward-looking statement. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.For more information please contact:HPIL Holding
Investor Relations
Tel:  +1 (248) 750-1015
Email: info@hpilholding.com 
inquiry@hpilholding.com
Source: HPIL Holding
Twitter:   https://twitter.com/hpilhold
Web Site: http://www.hpilholding.com
News: http://www.hpilholding.com/news/news.php
HPIL Holding  Tel:  +1(248) 750-1015 
Email: info@hpilholding.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/05/17/1826984/0/en/HPIL-HOLDING-issues-comprehensive-shareholder-update.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending